Personalized Diagnostics for Gene Editing Therapies

SeQure Dx specializes in providing comprehensive solutions for gene editing, focusing on the critical assessment of both on-target specificity and off-target risks associated with gene therapies. Their proprietary analytical tools are designed to deliver high sensitivity and scalability, enabling researchers and clinicians to evaluate gene editing outcomes effectively. This capability is essential for informing regulatory filings, guiding clinical trial designs, and ensuring patient safety by understanding the potential unintended consequences of genome modifications.

The company's technology is editor-agnostic, meaning it can be applied across various gene editing platforms, including CRISPR. SeQure Dx's diagnostics offer insights at both individual and population levels, supporting the entire development process from initial research to clinical application. By partnering with organizations like Integrated DNA Technologies (IDT), SeQure Dx aims to enhance the therapeutic development process, ultimately contributing to the safe and effective implementation of gene editing therapies in clinical settings.

United States

SeQure Dx, Inc. is applying genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Their GUIDE-seq and ONE-seq technologies enable identification of all potential off-target sites prior to initiating therapy, to allow comprehensive confirmation of actual edits.

SeQure Dx

Company Details